Trial Outcomes & Findings for Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation (NCT NCT02911805)

NCT ID: NCT02911805

Last Updated: 2025-12-05

Results Overview

Early Treatment Diabetic Retinopathy Study (ETDRS) chart was used. Higher scores mean a better outcome. The number of correct responses (e.g., number of letters read correctly) from a subject assessed prior to start of the first session of the the 12 week study was subtracted from the number of correct responses elicited at the end of the last session of the study. The means of these differences for each study group (Balance Training vs Aerobic Exercise) were compared by two-tailed t-test.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

NA

Target enrollment

14 participants

Primary outcome timeframe

12 weeks

Results posted on

2025-12-05

Participant Flow

Participant milestones

Participant milestones
Measure
Aerobic Exercise
Exercise 3 times a week Aerobic exercise: Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
Balance Training
Group balance training 3 times a week Balance exercise: Instructor-led exercises done in a group setting for strengthening, balance, flexibility
Overall Study
STARTED
6
8
Overall Study
COMPLETED
6
8
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Aerobic Exercise
n=6 Participants
Exercise 3 times a week Aerobic exercise: Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
Balance Training
n=8 Participants
Group balance training 3 times a week Balance exercise: Instructor-led exercises done in a group setting for strengthening, balance, flexibility
Total
n=14 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=37 Participants
0 Participants
n=37 Participants
0 Participants
n=74 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=37 Participants
0 Participants
n=37 Participants
0 Participants
n=74 Participants
Age, Categorical
>=65 years
6 Participants
n=37 Participants
8 Participants
n=37 Participants
14 Participants
n=74 Participants
Age, Continuous
73.7 years
STANDARD_DEVIATION 8.6 • n=37 Participants
73.1 years
STANDARD_DEVIATION 4.0 • n=37 Participants
73.4 years
STANDARD_DEVIATION 6.1 • n=74 Participants
Sex: Female, Male
Female
6 Participants
n=37 Participants
7 Participants
n=37 Participants
13 Participants
n=74 Participants
Sex: Female, Male
Male
0 Participants
n=37 Participants
1 Participants
n=37 Participants
1 Participants
n=74 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=37 Participants
0 Participants
n=37 Participants
0 Participants
n=74 Participants
Race (NIH/OMB)
Asian
0 Participants
n=37 Participants
0 Participants
n=37 Participants
0 Participants
n=74 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=37 Participants
0 Participants
n=37 Participants
0 Participants
n=74 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=37 Participants
3 Participants
n=37 Participants
6 Participants
n=74 Participants
Race (NIH/OMB)
White
2 Participants
n=37 Participants
2 Participants
n=37 Participants
4 Participants
n=74 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=37 Participants
0 Participants
n=37 Participants
0 Participants
n=74 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=37 Participants
3 Participants
n=37 Participants
4 Participants
n=74 Participants
Region of Enrollment
United States
6 Participants
n=37 Participants
8 Participants
n=37 Participants
14 Participants
n=74 Participants

PRIMARY outcome

Timeframe: 12 weeks

Population: As per baseline analysis population description.

Early Treatment Diabetic Retinopathy Study (ETDRS) chart was used. Higher scores mean a better outcome. The number of correct responses (e.g., number of letters read correctly) from a subject assessed prior to start of the first session of the the 12 week study was subtracted from the number of correct responses elicited at the end of the last session of the study. The means of these differences for each study group (Balance Training vs Aerobic Exercise) were compared by two-tailed t-test.

Outcome measures

Outcome measures
Measure
Aerobic Exercise
n=6 Participants
Exercise 3 times a week Aerobic exercise: Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
Balance Training
n=8 Participants
Group balance training 3 times a week Balance exercise: Instructor-led exercises done in a group setting for strengthening, balance, flexibility
Visual Acuity - Mean Acuity Change
7.333 Letters read correctly
Standard Deviation 8.501
-4.875 Letters read correctly
Standard Deviation 10.58

SECONDARY outcome

Timeframe: 12 weeks

Contrast sensitivity: The contrast sensitivity of the subjects will be measured with the Pelli-Robson Chart or Contrast Sensitivity Chart following the instructions provided with the chart. The two sides of the Pelli-Robson Chart have different letter sequences but are otherwise identical. The chart should be illuminated as uniformly as possible, so that the luminance of the white areas is between 80 and 120 cd/ m2 with no glare. The patient should sit directly in front of the chart at a distance of 1 meter (use the same 1 meter string as for visual acuity testing to measure the eye-to-chart distance). Subjects should be prevented from seeing the chart until the contrast sensitivity testing actually begins. Subjects should wear their best distance correction.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 weeks

Blood will be drawn prior to and after exercise sessions. From this, serum levels of brain derived neurotrophic factor (BDNF) will measured by immunoenzymatic assay.

Outcome measures

Outcome data not reported

Adverse Events

Aerobic Exercise

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Balance Training

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jeffrey H. Boatright, PhD

Atlanta VA

Phone: 404-321-6111

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place